In this comprehensive online program led by expert faculty, learn about implementation of rapid ART in newly diagnosed people with HIV, choosing an individualized first-line regimen for each patient, factors to consider when modifying therapy in virologically suppressed individuals or in patients with virologic failure, and evaluating patients for PrEP. Watch the Medical Minute videos and have your questions answered by faculty during the live webinars. Download the slides and patient education resources, listen to podcasts, and read the companion ClinicalThought commentaries.
In this case example, learn data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.
See data and recommendations for considering a switch to long-acting CAB plus RPV, including current indications and contraindications, data for “direct to inject” without an oral lead-in, and considerations for dosing every 8 weeks vs every 4 weeks.
A patient shares his experiences with switching from daily oral to long-acting antiretroviral therapy and how the change in treatment regimen better met his needs.
Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.
In this case example, learn data and recommendations for considering an ART switch following weight gain, including what is known about ART-associated weight gain and resulting metabolic complications, what the data are for switching, and what the guidelines recommend in this scenario.
See data and recommendations for considering an ART switch following weight gain, including what is known about ART-associated weight gain and resulting metabolic complications, what the data are for switching, and what the guidelines recommend in this scenario.
I’m doing really well on my current ART regimen, with the exception of the weight gain that I’ve recently noticed. I will manage my weight gain with lifestyle changes for now, and here are my reasons.
Should you continue or switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen? In this case example, learn about available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.
See available data and recommendations for the use of bictegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on a bictegravir-containing regimen.
Read my take on the factors to consider when contemplating a switch in antiretroviral therapy.
In this case example, learn about available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.
See available data and recommendations for the use of long-acting cabotegravir in pregnancy, as well as key considerations for deciding whether to switch ART for someone who becomes pregnant while virologically suppressed on long-acting cabotegravir and rilpivirine.
Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.
We should move from protecting pregnant women from research to protecting them through research. That’s how we can safely provide newer antiretroviral therapy options for people with HIV during pregnancy
The future must provide a way to decrease the therapeutic burden for people with HIV without compromising ART efficacy—improving the overall experience for the patient by doing more with less.
Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in pregnant people with HIV.
Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in pregnant people with HIV.
In this case example, learn about the history and current outbreak of monkeypox, as well as treatment guidance and considerations for people with HIV.
Hear from expert faculty as they answer questions and discuss monkeypox treatment and care considerations for people with HIV.
Hear from expert faculty as they answer questions and discuss monkeypox treatment and care considerations for people with HIV.
See the history and current outbreak of monkeypox, as well as treatment guidance and considerations for people with HIV.
In this case-based discussion, learn about considerations for ongoing PrEP candidacy, including PrEP considerations with adverse effects such as weight gain, and risk of HIV acquisition after discontinuing PrEP.
In this case-based discussion, learn about how technology and social media can affect PrEP adherence and persistence.
I understand that a relationship requires a certain level of vulnerability, but I’d rather not be physically vulnerable. I’ll let my emotional guards down, but my physical guards stay up. It’s not that I don’t trust the other person—but PrEP is something I do just for me.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.